Suntegrity's Zinc Oxide Sunscreen Recall: CGMP Deviations Trigger Global Supply Chain Review
Synchronicity Spa, Inc. DBA Suntegrity has initiated a Class II recall (D-0589-2024) for 8,202 tubes of its IMPECCABLE SKIN sunscreen foundation, citing CGMP Deviations. This action impacts global distribution of the Zinc Oxide-based product, necessitating immediate supply chain assessments and regulatory compliance reviews for procurement and regulatory affairs teams across affected markets.
FDA Enforcement: Synchronicity Spa's CGMP Deviations Trigger Class II Recall
Synchronicity Spa, Inc. DBA Suntegrity has initiated a Class II recall, identified as D-0589-2024, for 8,202 tubes of its IMPECCABLE SKIN sunscreen foundation. The primary reason cited for this voluntary, firm-initiated action is deviations from Current Good Manufacturing Practices (CGMP). This recall specifically targets a range of shades for the Zinc Oxide 15% Broad Spectrum SPF30 product, including IVORY (NDC: 69949-151-01, UPC: 854245006170), NUDE (NDC: 69949-156-01, UPC: 854245006224), BUFF (NDC: 69949-152-01, UPC: 854245006187), SAND (NDC: 69949-153-01, UPC: 854245006194), BRONZE (NDC: 69949-155-01, UPC: 854245006217), and MOCHA (NDC: 69949-157-01, UPC: 854245006446). These products are classified as human over-the-counter (OTC) drugs, with Zinc Oxide (UNII: SOI2LOH54Z) as the active ingredient. For procurement directors and regulatory affairs heads, this event underscores the critical importance of supplier adherence to CGMP. Deviations can compromise product quality, safety, and efficacy, leading to significant market disruptions and potential regulatory penalties. The recall initiation date was May 24, 2024, with the center classification date on July 8, 2024, indicating an ongoing regulatory process that requires close monitoring.
Suntegrity's Manufacturing Footprint and Product Portfolio Impacted
The recalled products originate from Synchronicity Spa, Inc. DBA Suntegrity, located at 2411 Tech Center Ct Ste 104, Las Vegas, NV 89128-0805, United States. This facility is responsible for manufacturing the IMPECCABLE SKIN sunscreen foundation, an OTC drug product registered under application number M020. The product, a topical formulation containing 15% Zinc Oxide, is designed for broad-spectrum SPF30 protection. While specific details on the facility's overall capacity or its role in the global API supply chain are not available, its involvement in producing a widely distributed OTC drug means any operational disruption or compliance issue has far-reaching implications. For business development executives, this highlights the inherent risks associated with relying on single-source manufacturers for finished drug products. Supply chain VPs must evaluate their exposure to this specific manufacturer and product line, considering the potential for stockouts and the need to identify alternative finished product suppliers or contract manufacturers capable of meeting stringent CGMP requirements for Zinc Oxide-based formulations. The ongoing status of the recall indicates that the company is actively engaged in addressing the identified deficiencies.
Global Supply Chain Exposure: Widespread Distribution of Recalled Sunscreen
The recall initiated by Synchronicity Spa, Inc. DBA Suntegrity has a significant global footprint, impacting markets well beyond the United States. The distribution pattern for the IMPECCABLE SKIN sunscreen foundation extends Nationwide in the USA, and internationally to Queensland, Christchurch, Ontario, Quebec, Alberta, British Columbia (Canada), Cayman Islands, Bermuda, France, Amsterdam, Hants, Dubai (UAE), Hong Kong, Singapore, and Taiwan. This broad reach means that procurement directors and supply chain VPs in these diverse geographies must immediately assess their inventory of the affected 8,202 tubes. The Class II classification, while not indicating an immediate life-threatening risk, still signifies that the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For regulatory affairs heads, managing this recall across multiple jurisdictions requires a nuanced understanding of each country's specific recall procedures, notification requirements, and potential penalties for non-compliance. Business development executives should anticipate potential brand reputation damage in these markets and prepare communication strategies to reassure distributors and consumers.
Strategic Sourcing: Identifying Alternatives for Zinc Oxide Formulations
Given the Class II recall of Synchronicity Spa, Inc. DBA Suntegrity's Zinc Oxide 15% sunscreen foundation due to CGMP deviations, procurement directors must prioritize the identification and qualification of alternative suppliers for similar topical formulations. While specific alternative suppliers for this particular product or active pharmaceutical ingredient (API) are not detailed in our current intelligence, the market for Zinc Oxide (UNII: SOI2LOH54Z) as a UV filter and skin protectant is robust. Companies should look for manufacturers specializing in mineral-based sunscreens or dermal products that demonstrate a strong track record of FDA compliance and robust CGMP adherence. Key considerations for qualification timelines include facility audits, documentation review, stability testing, and regulatory submissions, which can be extensive for OTC drug products. Geographic diversity in sourcing is crucial to mitigate future single-point-of-failure risks. Business development executives should explore partnerships with manufacturers in regions known for stringent quality control, ensuring that any new supplier can meet both regulatory requirements and consumer demand for high-quality, safe sunscreen products.
Broader Regulatory Context: Persistent CGMP Enforcement Trends
While our intelligence graph does not indicate prior regulatory actions specifically against Synchronicity Spa, Inc. DBA Suntegrity, this recall due to CGMP deviations aligns with a broader, intensified focus by the FDA on manufacturing quality across the pharmaceutical and OTC drug industries. Recent parallel events highlight this trend, with several high-profile recalls stemming from CGMP issues. For instance, Pfizer has faced Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter, underscoring severe manufacturing control failures. Similarly, Sandoz experienced a Class II recall for Enoxaparin Sodium due to critical CGMP temperature excursion risks. Teva Pharmaceuticals' Warfarin Sodium and Allergan's ARMOUR THYROID have also been subject to Class II recalls linked to Cardinal Healthcare's storage deviations, which constitute CGMP non-compliance. These examples demonstrate that the FDA is actively scrutinizing all aspects of manufacturing and supply chain integrity. For regulatory affairs heads and supply chain VPs, this means that investing in robust Quality Management Systems, continuous monitoring of contract manufacturing organizations (CMOs), and proactive risk assessments are not merely best practices but essential for maintaining market access and avoiding costly recalls.
Remediation Pathways and Future Outlook for Suntegrity's Compliance
The Class II recall (D-0589-2024) of Synchronicity Spa, Inc. DBA Suntegrity's IMPECCABLE SKIN sunscreen foundation is currently designated as 'Ongoing,' indicating that the firm is actively working to address the identified CGMP deviations. Typically, the FDA expects a comprehensive remediation plan from the recalling firm. This plan must include a thorough root cause analysis to identify the underlying reasons for the CGMP failures, followed by the implementation of robust corrective and preventive actions (CAPA). These actions often involve process improvements, equipment upgrades, enhanced quality control measures, and employee training. For regulatory affairs heads, monitoring the progress of this remediation is critical, as the FDA will assess the adequacy and effectiveness of these measures. Failure to demonstrate sustained compliance could lead to further regulatory actions, including potential Warning Letters, increased inspection frequency, or even import alerts for products distributed internationally. Business development executives should understand that the long-term market viability and brand reputation of Suntegrity's products will depend heavily on their ability to swiftly and effectively resolve these manufacturing quality issues and restore full confidence in their operational integrity.